STOP-CoV study results highlights importance of completing primary vaccine series
In a pre-print, not yet peer reviewed, the team from the STOP-CoV study, led by Dr. Sharon Walmsley from the University Health Network in Toronto, described their most recent findings: younger adults (30-50) generate higher levels of vaccine-specific antibodies compared to older adults (70 and above) after both the first and second mRNA vaccine doses.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed